Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Coherus biosciences, inc. symbols : ABBV save search
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.77%
H: 1.63%
C: 0.35%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.82%
H: 3.88%
C: 2.45%
chs-1000 preclinical for meeting
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
Published: 2024-03-13 (Crawled : 20:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -8.7%
H: 21.43%
C: 3.33%
business year update financial
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
Published: 2023-11-06 (Crawled : 21:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.28%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -22.6%
H: 3.28%
C: -9.85%
business financial results
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
Published: 2023-08-02 (Crawled : 20:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.28%
H: 0.27%
C: 0.06%
SURF | $1.07 -0.93% -1.41% 0
|
Health Technology
|
| O: 3.49%
H: 14.13%
C: 10.87%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 9.45%
H: 10.53%
C: 7.58%
business financial results
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
Published: 2023-06-05 (Crawled : 22:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.45%
H: 0.05%
C: -1.48%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.4%
H: 9.6%
C: 5.4%
piter-02 positive trial results
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
Published: 2023-05-08 (Crawled : 20:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.03%
H: 0.71%
C: -0.39%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -20.64%
H: 0.93%
C: -8.51%
business financial results
Coherus Names Paul Reider Chief Commercial Officer
Published: 2022-02-15 (Crawled : 23:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.24%
H: 1.47%
C: 0.98%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.77%
H: 2.82%
C: 0.53%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.33%
H: 0.52%
C: -0.47%
commercialization
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 positive bioscience results
Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
Published: 2021-11-15 (Crawled : 13:30) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.34%
H: 0.73%
C: -0.09%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.46%
H: 1.81%
C: 0.75%
orphan drug cancer drug granted designation
Coherus and Junshi Biosciences Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
Published: 2021-11-15 (Crawled : 13:30) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.34%
H: 0.73%
C: -0.09%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.46%
H: 1.81%
C: 0.75%
orphan drug cancer drug granted designation
Coherus BioSciences Announces CMS Has Extended Enhanced Medicare Reimbursement for UDENYCA® in the 340B Hospital Setting Through Year-End 2022
Published: 2021-11-05 (Crawled : 14:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.28%
H: 0.51%
C: 0.39%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.45%
H: 2.59%
C: 0.34%
Coherus and Junshi Biosciences Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal CarcinomaFDA has granted the toripalimab BLA Priority Review with a target action date of April 2022
Published: 2021-11-01 (Crawled : 12:15) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 2.72%
H: 0.41%
C: -0.38%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.49%
H: 3.83%
C: 0.0%
treatment fda fda acceptance granted
Coherus Announces Positive Results of UDENYCA® On-Body Injector Clinical Trial
Published: 2021-10-05 (Crawled : 13:15) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.61%
H: 1.09%
C: 0.11%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.25%
H: 4.54%
C: 2.02%
positive results positive results trial
Coherus Announces BLA Filing for Lucentis® (ranibizumab) Biosimilar Candidate Accepted by FDA for Review
Published: 2021-10-01 (Crawled : 20:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
fda biosimilar
Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-17 (Crawled : 01:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06
Published: 2021-09-16 (Crawled : 23:00) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.44%
H: 0.47%
C: -0.15%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: -0.7%
H: 2.3%
C: 2.23%
positive results
Coherus and Junshi Biosciences to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
Published: 2021-09-16 (Crawled : 23:00) - globenewswire.com
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 1.12%
H: 0.0%
C: 0.0%
treatment positive therapy results phase 3 trial cell carcinoma
Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab
Published: 2021-09-15 (Crawled : 13:15) - biospace.com/
ABBV | News | $164.66 0.25% -0.15% 4.5M
|
Health Technology
|
| O: 0.1%
H: 2.07%
C: 1.11%
CHRS | $1.99 -7.44% -8.04% 1.9M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: -2.29%
results phase 3
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.